Annual report pursuant to Section 13 and 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.22.4
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Preferred Stock
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Preferred Stock
Series C Preferred Stock
Common Stock
Additional Paid-in Capital
AOCI Attributable to Parent
Accumulated Deficit
Beginning balance at Dec. 31, 2020 $ (48,736) $ 52,809 $ 35,228 $ 65,222 $ 2 $ 10,131 $ (982) $ (211,146)
Beginning balance, shares at Dec. 31, 2020 [1]   21,615,723 8,306,818 12,804,176 17,664,015      
Exercise of stock options 1,289         1,289    
Exercise of stock options, shares [1]         923,200      
Stock compensation expense 11,634         11,634    
Issuance of common stock relating to the acquisition 19,362       $ 1 19,361    
Issuance of common stock relating to the acquisition, shares [1]         5,230,167      
Issuance of shares to FP Credit Partners. L.P 22,868         22,868    
Issuance of shares to FP Credit Partners. L.P., shares [1]         2,468,492      
Exercise of Series C preferred stock warrants 891     $ 891        
Exercise of Series C preferred warrants, Shares [1]       146,919        
Conversion of warrants to common stock 308         308    
Conversion of warrants to common stock, Share [1]         672,355      
Conversion of PS Series A to common stock   $ (52,809)     $ 2 52,807    
Conversion of PS Series A to common stock, shares [1]   (21,615,723)     21,615,723      
Conversion of PS Series B to common stock     $ (35,228)   $ 1 35,227    
Conversion of PS Series B to common stock, shares [1]     (8,306,818)   8,306,818      
Conversion of PS Series C to common stock       $ (66,113) $ 1 66,112    
Conversion of PS Series C to common stock, shares [1]       (12,951,095) 12,951,095      
Conversion of convertible notes to common stock 70,933       $ 4 70,929    
Conversion of convertible notes to common stock, shares [1]         37,034,620      
Issuance of common stock upon the reverse recapitalization, net of issuance costs 206,308       $ 4 206,304    
Issuance of common stock upon the reverse recapitalization, net of issuance costs, shares [1]         44,288,129      
Contingent earnout liability recognized upon the closing of the reverse recapitalization (58,274)         (58,274)    
Net loss (38,090)             (38,090)
Foreign currency translation adjustments 1,714           1,714  
Net unrealized loss on investments (net of tax) 0              
Ending balance at Dec. 31, 2021 190,207       $ 15 438,696 732 (249,236)
Ending balance, shares at Dec. 31, 2021 [1]         151,154,614      
Exercise of stock options $ 806         806    
Exercise of stock options, shares 503,805       503,805 [1]      
Stock compensation expense $ 11,491         11,491    
Exercise of Series C preferred stock warrants 0              
Conversion of warrants to common stock 4,206       $ 1 4,205    
Conversion of warrants to common stock, Share [1]         3,311,286      
Net loss (89,411)             (89,411)
Foreign currency translation adjustments (7,696)           (7,696)  
Release of Restricted Stock Units (70)         (70)    
Release of Restricted Stock Units, Shares [1]         242,486      
Issuance of common stock upon ESPP purchase 623         623    
Issuance of common stock upon ESPP purchase, shares [1]         525,808      
Net unrealized loss on investments (net of tax) (33)           (33)  
Ending balance at Dec. 31, 2022 $ 110,123       $ 16 $ 455,751 $ (6,997) $ (338,647)
Ending balance, shares at Dec. 31, 2022 [1]         155,737,999      
[1] (1) The shares of the Company’s common and convertible preferred stock, prior to the Merger (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of approximately 1.7058 established in the Merger.